Table 1.
Study Population Characteristics and Antimicrobial Exposure at Cohort Entry
| Characteristic | Total (n=1,299,056) | Amoxicillin (n=166,888) | Amoxicillin-clavulanic acid (n=178,047) | Cefuroxime (n=151,238) | Clarithr omycin (n=156,774) | Doxycycline (n=176,794) | Levofloxacin (n=181,332) | Moxifloxacin (n=176,934) | Telithromycin (n=79,357) | Current Multiple Use (n=31,692) |
|---|---|---|---|---|---|---|---|---|---|---|
| Age distribution at cohort entry (years) | ||||||||||
| 18–24 | 115,695 (8.9) | 17,063 (10) | 19,137 (11) | 16,353 (11) | 13,163 (8) | 22,200 (13) | 9915 (5) | 9088 (5) | 6905 (9) | 1807 (6) |
| 25–34 | 201,163 (15.5) | 26,172 (16) | 30,728 (17) | 25,212 (17) | 24,298 (15) | 31,517 (18) | 21,759 (12) | 22,488 (13) | 14,019 (18) | 4970 (16) |
| 35–44 | 280,157 (21.6) | 31,535 (19) | 39,045 (22) | 36,157 (24) | 35,898 (23) | 35,767 (20) | 35,346 (19) | 38,069 (22) | 20,634 (26) | 7644 (24) |
| 45–54 | 281,850 (21.7) | 30,575 (18) | 35,450 (20) | 34,287 (23) | 34,384 (22) | 33,201 (19) | 41,890 (23) | 44,357 (25) | 19,801 (25) | 7936 (25) |
| 55–64 | 203,881 (15.7) | 21,722 (13) | 22,102 (12) | 23,855 (16) | 21,397 (14) | 22,850 (13) | 37,214 (21) | 36,267 (20) | 12,828 (16) | 5680 (18) |
| 65–74 | 125,061 (9.6) | 22,521 (13) | 19,271 (11) | 8343 (6) | 18,466 (12) | 18,529 (10) | 17,476 (10) | 14,905 (8) | 3406 (4) | 2161 (7) |
| 75–84 | 67,474 (5.2) | 13,485 (8) | 9080 (5) | 4855 (3) | 7210 (5) | 9772 (6) | 12,227 (7) | 8396 (5) | 1367 (2) | 1108 (3) |
| 85+ | 23,775 (1.8) | 3815 (2) | 3234 (2) | 2176 (1) | 1958 (1) | 2958 (2) | 5505 (3) | 3364 (2) | 397 (1) | 386 (1) |
| Sex | ||||||||||
| Male | 567,346 (43.7) | 70,661 (42) | 81,855 (46) | 59,402 (39) | 69,917 (45) | 78,201 (44) | 79,216 (44) | 78,494 (44) | 33,859 (43) | 15,741 (50) |
| Female | 731,710 (56.3) | 96,227 (58) | 96,192 (54) | 91,836 (61) | 86,857 (55) | 98,593 (56) | 102,116 (56) | 98,440 (56) | 45,498 (57) | 15,951 (50) |
| Calendar year at cohort entry | ||||||||||
| 2001 | 46,713 (3.6) | 6421 (4) | 5687 (3) | 9224 (6) | 9209 (6) | 6963 (4) | 4309 (2) | 3308 (2) | 0 (0) | 1592 (5) |
| 2002 | 89,332 (6.9) | 11,954 (7) | 11,438 (6) | 14,568 (10) | 17,475 (11) | 12,939 (7) | 9781 (5) | 8008 (5) | 0 (0) | 3169 (10) |
| 2003 | 79,682 (6.1) | 10,454 (6) | 10,892 (6) | 10,678 (7) | 15,032 (10) | 11,379 (6) | 11,069 (6) | 7450 (4) | 0 (0) | 2728 (9) |
| 2004 | 162,543 (12.5) | 22,097 (13) | 21,547 (12) | 17,205 (11) | 20,704 (13) | 22,200 (13) | 23,105 (13) | 19,011 (11) | 12,748 (16) | 3926 (12) |
| 2005 | 265,856 (20.5) | 32,513 (19) | 32,166 (18) | 25,981 (17) | 30,385 (19) | 32,625 (18) | 34,861 (19) | 29,967 (17) | 42,516 (54) | 4842 (15) |
| 2006 | 235,133 (18.1) | 29,526 (18) | 30,891 (17) | 23,700 (16) | 24,244 (15) | 29,772 (17) | 34,834 (19) | 34,694 (20) | 22,067 (28) | 5405 (17) |
| 2007 | 220,427 (17.0) | 27,612 (17) | 32,846 (18) | 24,866 (16) | 21,225 (14) | 29,881 (17) | 34,520 (19) | 42,389 (24) | 1937 (2) | 5151 (16) |
| 2008 | 160,072 (12.3) | 21,191 (13) | 25,759 (14) | 19,511 (13) | 14,584 (9) | 25,180 (14) | 23,496 (13) | 26,341 (15) | 85 (0) | 3925 (12) |
| 2009 | 39,298 (3.0) | 5120 (3) | 6821 (4) | 5505 (4) | 3916 (2) | 5855 (3) | 5357 (3) | 5766 (3) | 4 (0) | 954 (3) |
Data are no. (%) of patients.
Patients counted as being exposed to each antimicrobial are those exposed to a single antimicrobial at cohort entry. Patients with current use of more than one antimicrobial at cohort entry are counted only in the column for current multiple use. Because of the sampling plan, the numbers of patients exposed to each of the antimicrobials at entry were similar except for those exposed to telithromycin, which was prescribed considerably less commonly than any of the other drugs.